Active Biotech
0.503 SEK +3.82%Be the first to follow this company
Active Biotech develops drugs in disease areas such as cancer and inflammatory diseases where the immune system plays a crucial role. The company's project portfolio contains both small orally active immunomodulatory molecules and antibody-based immunotherapy. The company focuses on projects in specialist indications in disease areas such as hematological cancer, inflammatory eye diseases, and solid tumors.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
ACTI
Daily low / high price
0.488 / 0.503
SEK
Market cap
181.99M SEK
Turnover
106.45K SEK
Volume
213K
Latest videos
Financial calendar
Interim report
2024-08-22
Interim report
2024-11-07
Annual report
2025-02-13
Interim report
2025-05-08
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
MGA Holding AB | 28.1 % | 28.1 % |
Sjuenda Holding | 7.4 % | 7.4 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Active Biotech enters agreement for a clinical study of tasquinimod in myelofibrosis
Antal aktier och röster i Active Biotech
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools